By Denny Jacob

Moderna Inc. on Friday said Health Canada authorized the use of its Omicron-targeting bivalent Covid-19 booster vaccine in children and adolescents 6-to-17-years old, bringing the offering to a greater portion of the population.

The pharmaceutical company said the pediatric and adolescent authorization is based on clinical trial booster data for its original vaccine, Spikevax, which was administered to over a thousand participants in each cohort.

Moderna's Omicron-targeting bivalent vaccines are currently authorized for use in individuals 18 years and older in Canada.

"The authorization of a booster dose of mRNA-1273.214 in children and adolescents is a critical step to broaden protection against the Omicron family of variants, and the emergence of new variants of concern in Canada," said Chief Executive Stéphane Bancel.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

February 17, 2023 11:31 ET (16:31 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Moderna.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Moderna.